DUALITYBIO-B (09606) announced its interim results, with research and development expenses totaling 607 million yuan, an increase of 73.64% year-on-year.

DUALITYBIO-B (09606) announced its interim results for the six months ending June 30, 2026, reporting a revenue of 219 million yuan; adjusted revenue of 510 million yuan; research and development expenses of 607 million yuan, an increase of 73.64% year-on-year; and an adjusted loss of 627 million yuan, with a loss per share of 10.2 yuan. In the first half of 2026, the company's product portfolio achieved a qualitative leap in its development stages: the first HER2 ADC drug, paclitaxel trastuzumab, received acceptance for its BLA, and the B7-H3 ADC drug, elfetabart drozuntecan, initiated its first Phase 3 clinical trial. The combination of ADC with next-generation immunotherapy (IO) strategies obtained verification of frontline clinical data, while the company began expanding the economic rights of the B7-H3 ADC project in the United States. Following the reporting period, the company entered into a collaboration and licensing agreement with Genentech. As of June 30, 2026, the company's clinical trials were underway in around 20 countries, enrolling over 3,500 patients, with approximately 50% from the United States, the European Union, Australia, and other regions outside of China. The company's progress in the first half of 2026 focused on four areas: advancing core products into critical stages and registration; collaborating with BioNTech to promote the ADC + next-generation IO combination strategy; continuously driving platform-driven innovation in oncology and autoimmune diseases; and enhancing the value and coverage of the company's global partnership landscape. In addition to these achievements, the company implemented a share buyback program, demonstrating its firm confidence in the long-term value of the company.